{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:21:32Z","timestamp":1770974492503,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pre-existing anti-adenovirus (Ad) neutralizing antibodies (AdNAbs) are a major barrier in clinical gene therapy using Ad vectors and oncolytic Ads; however, it has not been fully elucidated which Ad capsid protein-specific antibodies are involved in AdNAb-mediated inhibition of Ad infection <jats:italic>in vivo<\/jats:italic>. In this study, mice possessing antibodies specific for each Ad capsid protein were prepared by intramuscular electroporation of each Ad capsid protein-expressing plasmid. Ad vector-mediated hepatic transduction was efficiently inhibited by more than 100-fold in mice immunized with a fiber protein-expressing plasmid or a penton base-expressing plasmid. An Ad vector pre-coated with FX before administration mediated more than 100-fold lower transduction efficiencies in the liver of warfarinized mice immunized with a fiber protein-expressing plasmid or a penton base-expressing plasmid, compared with those in the liver of warfarinized non-immunized mice. These data suggest that anti-fiber protein and anti-penton base antibodies bind to an Ad vector even though FX has already bound to the hexon, and inhibit Ad vector-mediated transduction. This study provides important clues for the development of a novel Ad vector that can circumvent inhibition with AdNAbs.<\/jats:p>","DOI":"10.1038\/s41598-018-30947-z","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T09:51:55Z","timestamp":1534153915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antibodies against adenovirus fiber and penton base proteins inhibit adenovirus vector-mediated transduction in the liver following systemic administration"],"prefix":"10.1038","volume":"8","author":[{"given":"Kyoko","family":"Tomita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminori","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahisa","family":"Hemmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisaku","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Machitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Mizuguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"30947_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","volume":"13","author":"IV Dolzhikova","year":"2017","unstructured":"Dolzhikova, I. V. et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I\/II trial in healthy adults in Russia. Hum Vaccin Immunother 13, 613\u2013620, https:\/\/doi.org\/10.1080\/21645515.2016.1238535 (2017).","journal-title":"Hum Vaccin Immunother"},{"key":"30947_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/infdis\/jiw244","volume":"214","author":"T Rampling","year":"2016","unstructured":"Rampling, T. et al. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S\/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. J Infect Dis 214, 772\u2013781, https:\/\/doi.org\/10.1093\/infdis\/jiw244 (2016).","journal-title":"J Infect Dis"},{"key":"30947_CR3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ijc.28696","volume":"135","author":"S Bramante","year":"2014","unstructured":"Bramante, S. et al. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer 135, 720\u2013730, https:\/\/doi.org\/10.1002\/ijc.28696 (2014).","journal-title":"Int J Cancer"},{"key":"30947_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00262-015-1706-4","volume":"64","author":"JP Balint","year":"2015","unstructured":"Balint, J. P. et al. Extended evaluation of a phase 1\/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunol Immunother 64, 977\u2013987, https:\/\/doi.org\/10.1007\/s00262-015-1706-4 (2015).","journal-title":"Cancer Immunol Immunother"},{"key":"30947_CR5","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-04-0765","volume":"10","author":"V Tsai","year":"2004","unstructured":"Tsai, V. et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 10, 7199\u20137206, https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0765 (2004).","journal-title":"Clin Cancer Res"},{"key":"30947_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1006\/mthe.2002.0669","volume":"6","author":"MT Vlachaki","year":"2002","unstructured":"Vlachaki, M. T. et al. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther 6, 342\u2013348 (2002).","journal-title":"Mol Ther"},{"key":"30947_CR7","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1128\/JCM.00156-11","volume":"49","author":"MP Walsh","year":"2011","unstructured":"Walsh, M. P. et al. Computational analysis of two species C human adenoviruses provides evidence of a novel virus. J Clin Microbiol 49, 3482\u20133490, https:\/\/doi.org\/10.1128\/JCM.00156-11 (2011).","journal-title":"J Clin Microbiol"},{"key":"30947_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1128\/JVI.06254-11","volume":"86","author":"RR Bradley","year":"2012","unstructured":"Bradley, R. R., Lynch, D. M., Iampietro, M. J., Borducchi, E. N. & Barouch, D. H. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol 86, 625\u2013629, https:\/\/doi.org\/10.1128\/JVI.06254-11 (2012).","journal-title":"J Virol"},{"key":"30947_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1182\/blood-2009-03-208835","volume":"114","author":"R Alba","year":"2009","unstructured":"Alba, R. et al. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114, 965\u2013971, https:\/\/doi.org\/10.1182\/blood-2009-03-208835 (2009).","journal-title":"Blood"},{"key":"30947_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/jmv.21721","volume":"82","author":"R Pilankatta","year":"2010","unstructured":"Pilankatta, R., Chawla, T., Khanna, N. & Swaminathan, S. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines. J Med Virol 82, 407\u2013414, https:\/\/doi.org\/10.1002\/jmv.21721 (2010).","journal-title":"J Med Virol"},{"key":"30947_CR11","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1016\/j.vaccine.2011.03.042","volume":"29","author":"C Sun","year":"2011","unstructured":"Sun, C. et al. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine 29, 3837\u20133841 (2011).","journal-title":"Vaccine"},{"key":"30947_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.virol.2012.12.014","volume":"437","author":"B Yu","year":"2013","unstructured":"Yu, B. et al. Characteristics of neutralizing antibodies to adenovirus capsid proteins in human and animal sera. Virology 437, 118\u2013123 (2013).","journal-title":"Virology"},{"key":"30947_CR13","doi-asserted-by":"publisher","first-page":"e33920","DOI":"10.1371\/journal.pone.0033920","volume":"7","author":"JT Bruder","year":"2012","unstructured":"Bruder, J. T. et al. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. PLoS One 7, e33920 (2012).","journal-title":"PLoS One"},{"key":"30947_CR14","doi-asserted-by":"publisher","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","volume":"174","author":"SM Sumida","year":"2005","unstructured":"Sumida, S. M. et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174, 7179\u20137185 (2005).","journal-title":"J Immunol"},{"key":"30947_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1128\/JVI.01878-08","volume":"83","author":"AL Parker","year":"2009","unstructured":"Parker, A. L. et al. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J Virol 83, 479\u2013483, https:\/\/doi.org\/10.1128\/JVI.01878-08 (2009).","journal-title":"J Virol"},{"key":"30947_CR16","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1128\/JVI.06165-11","volume":"86","author":"RR Bradley","year":"2012","unstructured":"Bradley, R. R. et al. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol 86, 1267\u20131272, https:\/\/doi.org\/10.1128\/JVI.06165-11 (2012).","journal-title":"J Virol"},{"key":"30947_CR17","doi-asserted-by":"publisher","first-page":"10366","DOI":"10.1128\/JVI.77.19.10366-10375.2003","volume":"77","author":"SS Hong","year":"2003","unstructured":"Hong, S. S., Habib, N. A., Franqueville, L., Jensen, S. & Boulanger, P. A. Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J Virol 77, 10366\u201310375 (2003).","journal-title":"J Virol"},{"key":"30947_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature04721","volume":"441","author":"DM Roberts","year":"2006","unstructured":"Roberts, D. M. et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239\u2013243 (2006).","journal-title":"Nature"},{"key":"30947_CR19","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1172\/JCI39812","volume":"120","author":"T Shiratsuchi","year":"2010","unstructured":"Shiratsuchi, T., Rai, U., Krause, A., Worgall, S. & Tsuji, M. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 120, 3688\u20133701, https:\/\/doi.org\/10.1172\/JCI39812 (2010).","journal-title":"J Clin Invest"},{"key":"30947_CR20","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.1128\/JVI.72.12.10260-10264.1998","volume":"72","author":"JG Gall","year":"1998","unstructured":"Gall, J. G., Crystal, R. G. & Falck-Pedersen, E. Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J Virol 72, 10260\u201310264 (1998).","journal-title":"J Virol"},{"key":"30947_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.gt.3301152","volume":"7","author":"Y Stallwood","year":"2000","unstructured":"Stallwood, Y., Fisher, K. D., Gallimore, P. H. & Mautner, V. Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients. Gene Ther 7, 637\u2013643, https:\/\/doi.org\/10.1038\/sj.gt.3301152 (2000).","journal-title":"Gene Ther"},{"key":"30947_CR22","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1128\/JVI.72.3.2388-2397.1998","volume":"72","author":"H Gahery-Segard","year":"1998","unstructured":"Gahery-Segard, H. et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol 72, 2388\u20132397 (1998).","journal-title":"J Virol"},{"key":"30947_CR23","first-page":"439","volume":"10","author":"AL Parker","year":"2008","unstructured":"Parker, A. L., Nicklin, S. A. & Baker, A. H. Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. Curr Opin Mol Ther 10, 439\u2013448 (2008).","journal-title":"Curr Opin Mol Ther"},{"key":"30947_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","volume":"132","author":"SN Waddington","year":"2008","unstructured":"Waddington, S. N. et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397\u2013409, https:\/\/doi.org\/10.1016\/j.cell.2008.01.016 (2008).","journal-title":"Cell"},{"key":"30947_CR25","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1525-0016(03)00243-0","volume":"8","author":"F Sakurai","year":"2003","unstructured":"Sakurai, F., Mizuguchi, H., Yamaguchi, T. & Hayakawa, T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 8, 813\u2013821 (2003).","journal-title":"Mol Ther"},{"key":"30947_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0378-1119(02)00410-9","volume":"285","author":"H Mizuguchi","year":"2002","unstructured":"Mizuguchi, H. & Hayakawa, T. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 285, 69\u201377 (2002).","journal-title":"Gene"},{"key":"30947_CR27","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1016\/j.biomaterials.2012.02.011","volume":"33","author":"H Matsui","year":"2012","unstructured":"Matsui, H. et al. A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X. Biomaterials 33, 3743\u20133755, https:\/\/doi.org\/10.1016\/j.biomaterials.2012.02.011 (2012).","journal-title":"Biomaterials"},{"key":"30947_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/sj.gt.3301701","volume":"9","author":"H Mizuguchi","year":"2002","unstructured":"Mizuguchi, H. et al. CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther 9, 769\u2013776, https:\/\/doi.org\/10.1038\/sj.gt.3301701 (2002).","journal-title":"Gene Ther"},{"key":"30947_CR29","doi-asserted-by":"publisher","first-page":"13062","DOI":"10.1128\/JVI.77.24.13062-13072.2003","volume":"77","author":"N Koizumi","year":"2003","unstructured":"Koizumi, N. et al. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J Virol 77, 13062\u201313072 (2003).","journal-title":"J Virol"},{"key":"30947_CR30","doi-asserted-by":"publisher","first-page":"11284","DOI":"10.1128\/JVI.75.23.11284-11291.2001","volume":"75","author":"DA Einfeld","year":"2001","unstructured":"Einfeld, D. A. et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 75, 11284\u201311291, https:\/\/doi.org\/10.1128\/JVI.75.23.11284-11291.2001 (2001).","journal-title":"J Virol"},{"key":"30947_CR31","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S1525-0016(03)00182-5","volume":"8","author":"K Martin","year":"2003","unstructured":"Martin, K. et al. Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther 8, 485\u2013494 (2003).","journal-title":"Mol Ther"},{"key":"30947_CR32","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1073\/pnas.0711757105","volume":"105","author":"O Kalyuzhniy","year":"2008","unstructured":"Kalyuzhniy, O. et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 105, 5483\u20135488, https:\/\/doi.org\/10.1073\/pnas.0711757105 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"30947_CR33","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.72.8.6875-6879.1998","volume":"72","author":"S Roy","year":"1998","unstructured":"Roy, S., Shirley, P. S., McClelland, A. & Kaleko, M. Circumvention of immunity to the adenovirus major coat protein hexon. J Virol 72, 6875\u20136879 (1998).","journal-title":"J Virol"},{"key":"30947_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bios.2014.04.025","volume":"60","author":"B Sikarwar","year":"2014","unstructured":"Sikarwar, B. et al. Surface plasmon resonance characterization of monoclonal and polyclonal antibodies of malaria for biosensor applications. Biosens Bioelectron 60, 201\u2013209, https:\/\/doi.org\/10.1016\/j.bios.2014.04.025 (2014).","journal-title":"Biosens Bioelectron"},{"key":"30947_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/jmv.23753","volume":"86","author":"TN Athmaram","year":"2014","unstructured":"Athmaram, T. N. et al. Characterization of pandemic influenza A (H1N1) virus hemagglutinin specific polyclonal antibodies for biosensor applications. J Med Virol 86, 363\u2013371, https:\/\/doi.org\/10.1002\/jmv.23753 (2014).","journal-title":"J Med Virol"},{"key":"30947_CR36","doi-asserted-by":"publisher","first-page":"e0192353","DOI":"10.1371\/journal.pone.0192353","volume":"13","author":"AW Harmon","year":"2018","unstructured":"Harmon, A. W., Moitra, R., Xu, Z. & Byrnes, A. P. Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum. PLoS One 13, e0192353, https:\/\/doi.org\/10.1371\/journal.pone.0192353 (2018).","journal-title":"PLoS One"},{"key":"30947_CR37","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/sj.gt.3301453","volume":"8","author":"H Mizuguchi","year":"2001","unstructured":"Mizuguchi, H. et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 8, 730\u2013735, https:\/\/doi.org\/10.1038\/sj.gt.3301453 (2001).","journal-title":"Gene Ther"},{"key":"30947_CR38","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.1128\/JVI.00445-09","volume":"83","author":"L Coughlan","year":"2009","unstructured":"Coughlan, L. et al. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol 83, 6416\u20136428, https:\/\/doi.org\/10.1128\/JVI.00445-09 (2009).","journal-title":"J Virol"},{"key":"30947_CR39","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1089\/10430349950017635","volume":"10","author":"K Bouri","year":"1999","unstructured":"Bouri, K. et al. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Hum Gene Ther 10, 1633\u20131640, https:\/\/doi.org\/10.1089\/10430349950017635 (1999).","journal-title":"Hum Gene Ther"},{"key":"30947_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jgm.1565","volume":"13","author":"M Raki","year":"2011","unstructured":"Raki, M. et al. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. J Gene Med 13, 253\u2013261, https:\/\/doi.org\/10.1002\/jgm.1565 (2011).","journal-title":"J Gene Med"},{"key":"30947_CR41","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/gt.2008.56","volume":"15","author":"M Sarkioja","year":"2008","unstructured":"Sarkioja, M. et al. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther 15, 921\u2013929, https:\/\/doi.org\/10.1038\/gt.2008.56 (2008).","journal-title":"Gene Ther"},{"key":"30947_CR42","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1128\/JVI.00866-09","volume":"84","author":"C Cheng","year":"2010","unstructured":"Cheng, C. et al. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 84, 630\u2013638, https:\/\/doi.org\/10.1128\/JVI.00866-09 (2010).","journal-title":"J Virol"},{"key":"30947_CR43","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1093\/emboj\/cdg614","volume":"22","author":"H Wodrich","year":"2003","unstructured":"Wodrich, H. et al. Switch from capsid protein import to adenovirus assembly by cleavage of nuclear transport signals. EMBO J 22, 6245\u20136255, https:\/\/doi.org\/10.1093\/emboj\/cdg614 (2003).","journal-title":"EMBO J"},{"key":"30947_CR44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0092-8674(82)90134-9","volume":"31","author":"CL Cepko","year":"1982","unstructured":"Cepko, C. L. & Sharp, P. A. Assembly of adenovirus major capsid protein is mediated by a nonvirion protein. Cell 31, 407\u2013415 (1982).","journal-title":"Cell"},{"key":"30947_CR45","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1089\/10430349950017374","volume":"10","author":"H Mizuguchi","year":"1999","unstructured":"Mizuguchi, H. & Kay, M. A. A simple method for constructing E1- and E1\/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 10, 2013\u20132017, https:\/\/doi.org\/10.1089\/10430349950017374 (1999).","journal-title":"Hum Gene Ther"},{"key":"30947_CR46","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.4049\/jimmunol.180.7.4931","volume":"180","author":"H Sakurai","year":"2008","unstructured":"Sakurai, H. et al. Adenoviral expression of suppressor of cytokine signaling-1 reduces adenovirus vector-induced innate immune responses. J Immunol 180, 4931\u20134938 (2008).","journal-title":"J Immunol"},{"key":"30947_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0042-6822(68)90121-9","volume":"36","author":"JV Maizel","year":"1968","unstructured":"Maizel, J. V., White, D. O. & Scharff, M. D. The polypeptides of adenovirus: I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36, 115\u2013125 (1968).","journal-title":"Virology"},{"key":"30947_CR48","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.1016\/j.vaccine.2012.09.046","volume":"30","author":"M Shoji","year":"2012","unstructured":"Shoji, M. et al. Intramuscular DNA immunization with in vivo electroporation induces antigen-specific cellular and humoral immune responses in both systemic and gut-mucosal compartments. Vaccine 30, 7278\u20137285 (2012).","journal-title":"Vaccine"},{"key":"30947_CR49","doi-asserted-by":"publisher","first-page":"14035","DOI":"10.1038\/mtm.2014.35","volume":"1","author":"K Shimizu","year":"2014","unstructured":"Shimizu, K. et al. Suppression of leaky expression of adenovirus genes by insertion of microRNA-targeted sequences in the replication-incompetent adenovirus vector genome. Mol Ther Methods Clin Dev 1, 14035, https:\/\/doi.org\/10.1038\/mtm.2014.35 (2014).","journal-title":"Mol Ther Methods Clin Dev"},{"key":"30947_CR50","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/sj.cgt.7700440","volume":"9","author":"H Mizuguchi","year":"2002","unstructured":"Mizuguchi, H. & Hayakawa, T. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther 9, 236\u2013242, https:\/\/doi.org\/10.1038\/sj.cgt.7700440 (2002).","journal-title":"Cancer Gene Ther"},{"key":"30947_CR51","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1089\/hum.2006.17.264","volume":"17","author":"N Koizumi","year":"2006","unstructured":"Koizumi, N. et al. Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther 17, 264\u2013279, https:\/\/doi.org\/10.1089\/hum.2006.17.264 (2006).","journal-title":"Hum Gene Ther"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30947-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30947-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30947-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T08:26:50Z","timestamp":1671611210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30947-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["30947"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-30947-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]},"assertion":[{"value":"10 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12315"}}